Trgovina Anixa Biosciences, Inc. - ANIX CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Pogoji trgovanja
| Razmik | 0.23 | ||||||||
|
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.024068% | ||||||||
|
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.001846% | ||||||||
| Čas nočne pristojbine | 21:00 (UTC) | ||||||||
| Min. tržena količina | 1 | ||||||||
| Valuta | USD | ||||||||
| Kritje | 20% | ||||||||
| Borza | United States of America | ||||||||
| Provizija na trgovanje | 0% |
*Information provided by Capital.com
Ključni statistični podatki
| Predhodno. Zapri* | 2.97 |
| Odpri* | 2.94 |
| Enoletna sprememba* | -1.67% |
| Dnevni razpon* | 2.9 - 3.04 |
| Razpon 52 wk | 2.50-6.25 |
| Povprečni obseg (10 dni) | 85.69K |
| Povprečni obseg (3 meseci) | 1.09M |
| Tržna kapitalizacija | 125.25M |
| Razmerje P/E | -100.00K |
| Število delnic v obtoku | 30.92M |
| Prihodki | N/A |
| EPS | -0.45 |
| Dividenda (donosnost v %) | N/A |
| Beta | 0.97 |
| Datum naslednjega zaslužka | N/A |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 2.99 | 0.05 | 1.70% | 2.94 | 3.08 | 2.90 |
| Jun 28, 2022 | 2.97 | -0.04 | -1.33% | 3.01 | 3.14 | 2.95 |
| Jun 27, 2022 | 3.16 | 0.15 | 4.98% | 3.01 | 3.19 | 3.01 |
| Jun 24, 2022 | 3.04 | 0.07 | 2.36% | 2.97 | 3.12 | 2.97 |
| Jun 23, 2022 | 3.13 | 0.11 | 3.64% | 3.02 | 3.19 | 3.02 |
| Jun 22, 2022 | 3.18 | 0.21 | 7.07% | 2.97 | 3.18 | 2.97 |
| Jun 21, 2022 | 3.08 | 0.06 | 1.99% | 3.02 | 3.19 | 3.02 |
| Jun 17, 2022 | 3.00 | -0.16 | -5.06% | 3.16 | 3.16 | 2.96 |
| Jun 16, 2022 | 3.10 | 0.15 | 5.08% | 2.95 | 3.18 | 2.90 |
| Jun 15, 2022 | 3.08 | 0.29 | 10.39% | 2.79 | 3.15 | 2.79 |
| Jun 14, 2022 | 2.88 | -0.18 | -5.88% | 3.06 | 3.09 | 2.82 |
| Jun 13, 2022 | 3.07 | -0.18 | -5.54% | 3.25 | 3.31 | 3.04 |
| Jun 10, 2022 | 3.33 | -0.10 | -2.92% | 3.43 | 3.48 | 3.27 |
| Jun 9, 2022 | 3.48 | 0.07 | 2.05% | 3.41 | 3.68 | 3.41 |
| Jun 8, 2022 | 3.50 | 0.23 | 7.03% | 3.27 | 3.54 | 3.27 |
| Jun 7, 2022 | 3.38 | -0.49 | -12.66% | 3.87 | 3.91 | 3.30 |
| Jun 6, 2022 | 3.92 | -0.27 | -6.44% | 4.19 | 4.44 | 3.87 |
| Jun 3, 2022 | 3.94 | 0.16 | 4.23% | 3.78 | 3.96 | 3.61 |
| Jun 2, 2022 | 3.81 | 0.01 | 0.26% | 3.80 | 3.85 | 3.74 |
| Jun 1, 2022 | 3.69 | 0.18 | 5.13% | 3.51 | 3.70 | 3.37 |
Anixa Biosciences, Inc. Events
| Čas (UTC) (UTC) | Država | Dogodek |
|---|---|---|
| No events scheduled | ||
- Letni
- Četrtletno
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Skupni prihodki | 0.5125 | 0 | 0.25 | 1.1125 | 0.3625 |
| Prihodki | 0.5125 | 0 | 0.25 | 1.1125 | 0.3625 |
| Celotni odhodki iz poslovanja | 13.6482 | 9.9782 | 12.14 | 15.4016 | 4.89048 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 7.0735 | 5.597 | 5.66283 | 6.91183 | 4.41068 |
| Raziskave in razvoj | 6.18969 | 4.38121 | 5.47343 | 6.81304 | 1.59755 |
| Depreciation / Amortization | 0 | 0.41875 | 0.3253 | 0.3253 | |
| Nenavadni odhodki (prihodki) | 0.385 | 0 | 0.585 | 1.35139 | -1.5345 |
| Other Operating Expenses, Total | 0.09145 | ||||
| Prihodki iz poslovanja | -13.1357 | -9.9782 | -11.89 | -14.2891 | -4.52798 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 0.00232 | 0.03392 | 0.07135 | 0.04597 | -0.48102 |
| Čisti dobiček pred obdavčitvijo | -13.1279 | -10.0924 | -11.8187 | -14.2431 | -5.00899 |
| Čisti dobiček po davkih | -13.1279 | -10.0924 | -11.8187 | -14.2431 | -5.00899 |
| Čisti dobiček pred dodatnimi postavkami | -12.9544 | -10.0184 | -11.647 | -13.996 | -5.00899 |
| Čisti dobiček | -12.9544 | -10.0184 | -11.647 | -13.996 | -5.00899 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -12.9544 | -10.0184 | -11.647 | -13.996 | -7.01777 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -12.9544 | -10.0184 | -11.647 | -13.996 | -7.01777 |
| Popravljen čisti dobiček | -12.9544 | -10.0184 | -11.647 | -13.996 | -7.01777 |
| Popravljene ponderirane povprečne delnice | 28.5789 | 22.229 | 19.7898 | 17.6243 | 12.1973 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.45329 | -0.45069 | -0.58854 | -0.79413 | -0.57535 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Popravljen normalizirani dobiček na enoto čistega dobička | -0.44 | -0.44403 | -0.55898 | -0.71745 | -0.70116 |
| Total Adjustments to Net Income | 0 | -2.00878 | |||
| Manjšinski delež | 0.17352 | 0.07401 | 0.1716 | 0.24706 | |
| Gain (Loss) on Sale of Assets | 0.00545 | -0.14808 |
| Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | |
|---|---|---|---|---|---|
| Skupni prihodki | 0 | 0 | 0 | 0 | 0 |
| Prihodki | 0 | 0 | 0 | 0 | 0 |
| Celotni odhodki iz poslovanja | 3.589 | 3.88 | 4.07704 | 4.38824 | 2.43728 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 1.854 | 2.042 | 1.9038 | 2.22161 | 1.41511 |
| Raziskave in razvoj | 1.735 | 1.838 | 2.17324 | 2.16662 | 1.02218 |
| Nenavadni odhodki (prihodki) | 0 | 0 | 0 | 0 | 0 |
| Prihodki iz poslovanja | -3.589 | -3.88 | -4.07704 | -4.38824 | -2.43728 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 0.001 | 0.001 | 0.00055 | 0.00063 | 0.00039 |
| Čisti dobiček pred obdavčitvijo | -3.588 | -3.879 | -4.07105 | -4.38761 | -2.43689 |
| Čisti dobiček po davkih | -3.588 | -3.879 | -4.07105 | -4.38761 | -2.43689 |
| Manjšinski delež | 0.044 | 0.05 | 0.05778 | 0.05362 | 0.03804 |
| Čisti dobiček pred dodatnimi postavkami | -3.544 | -3.829 | -4.01327 | -4.33399 | -2.39885 |
| Čisti dobiček | -3.544 | -3.829 | -4.01327 | -4.33399 | -2.39885 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -3.544 | -3.829 | -4.01327 | -4.33399 | -2.39885 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -3.544 | -3.829 | -4.01327 | -4.33399 | -2.39885 |
| Popravljen čisti dobiček | -3.544 | -3.829 | -4.01327 | -4.33399 | -2.39885 |
| Popravljene ponderirane povprečne delnice | 30.152 | 30.125 | 30.0451 | 30.4553 | 28.6695 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.11754 | -0.1271 | -0.13357 | -0.14231 | -0.08367 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Popravljen normalizirani dobiček na enoto čistega dobička | -0.11754 | -0.1271 | -0.13376 | -0.14231 | -0.08367 |
| Gain (Loss) on Sale of Assets | 0.00545 |
- Letni
- Četrtletno
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 36.0034 | 9.36862 | 6.09312 | 5.53837 | 7.01394 |
| Denarna sredstva in kratkoročne naložbe | 35.7279 | 9.05706 | 5.84163 | 5.05589 | 6.83937 |
| Denarna sredstva in ustrezniki | 29.1283 | 6.41706 | 3.49163 | 3.05589 | 3.33937 |
| Kratkoročne naložbe | 6.5996 | 2.64 | 2.35 | 2 | 3.5 |
| Prepaid Expenses | 0.27556 | 0.30933 | 0.18497 | 0.17549 | 0.17457 |
| Total Assets | 36.2574 | 9.45296 | 6.29369 | 6.44854 | 8.81242 |
| Property/Plant/Equipment, Total - Net | 0.25396 | 0.05434 | 0.20057 | 0.07267 | 0.0527 |
| Property/Plant/Equipment, Total - Gross | 0 | 0.29558 | 0.12647 | 0.08843 | |
| Accumulated Depreciation, Total | 0 | -0.09502 | -0.0538 | -0.03573 | |
| Intangibles, Net | 0 | 0.8375 | 1.74578 | ||
| Total Current Liabilities | 1.27053 | 1.18859 | 1.48132 | 1.26511 | 0.88949 |
| Accounts Payable | 0.1362 | 0.23237 | 0.58582 | 0.58201 | 0.48032 |
| Accrued Expenses | 1.13433 | 0.95622 | 0.8955 | 0.6831 | 0.40917 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 0.8201 | 0.69161 | 1.05834 | 1.01373 | 0.88949 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.22008 | 0 | |||
| Total Equity | 35.4373 | 8.76136 | 5.23535 | 5.43481 | 7.92292 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.30051 | 0.24249 | 0.20332 | 0.18909 | 0.16603 |
| Additional Paid-In Capital | 239.927 | 200.354 | 186.849 | 175.416 | 163.931 |
| Retained Earnings (Accumulated Deficit) | -204.79 | -191.836 | -181.817 | -170.17 | -156.174 |
| Total Liabilities & Shareholders’ Equity | 36.2574 | 9.45296 | 6.29369 | 6.44854 | 8.81242 |
| Total Common Shares Outstanding | 30.0509 | 24.2487 | 20.3318 | 18.9086 | 16.6028 |
| Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
| Celotne terjatve, neto | 0.00223 | 0.06653 | 0.30699 | ||
| Accounts Receivable - Trade, Net | 0.00223 | 0.06653 | 0.30699 | ||
| Minority Interest | -0.67051 | -0.49698 | -0.42298 | -0.25138 | |
| Other Long Term Assets, Total | 0 | 0.03 |
| Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 32.563 | 34.994 | 36.0034 | 37.052 | 38.472 |
| Denarna sredstva in kratkoročne naložbe | 32.231 | 34.53 | 35.7279 | 36.622 | 38.1027 |
| Denarna sredstva in ustrezniki | 27.732 | 29.781 | 29.1283 | 27.2222 | 27.7034 |
| Kratkoročne naložbe | 4.499 | 4.749 | 6.5996 | 9.39978 | 10.3993 |
| Prepaid Expenses | 0.332 | 0.464 | 0.27556 | 0.43001 | 0.36921 |
| Total Assets | 32.797 | 35.238 | 36.2574 | 37.0624 | 38.4975 |
| Property/Plant/Equipment, Total - Net | 0.234 | 0.244 | 0.25396 | 0.01041 | 0.02557 |
| Other Long Term Assets, Total | 0 | 0 | 0 | ||
| Total Current Liabilities | 1.189 | 1.787 | 1.27053 | 1.20802 | 1.44287 |
| Accounts Payable | 0.093 | 0.504 | 0.1362 | 0.20773 | 0.43801 |
| Accrued Expenses | 1.096 | 1.283 | 1.13433 | 1.00029 | 1.00486 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.626 | 1.275 | 0.8201 | 0.5953 | 0.88376 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -0.765 | -0.721 | -0.67051 | -0.61273 | -0.55911 |
| Total Equity | 32.171 | 33.963 | 35.4373 | 36.4671 | 37.6138 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.302 | 0.301 | 0.30051 | 0.2995 | 0.3145 |
| Additional Paid-In Capital | 244.032 | 242.281 | 239.927 | 236.944 | 233.742 |
| Retained Earnings (Accumulated Deficit) | -212.163 | -208.619 | -204.79 | -200.777 | -196.443 |
| Total Liabilities & Shareholders’ Equity | 32.797 | 35.238 | 36.2574 | 37.0624 | 38.4975 |
| Total Common Shares Outstanding | 30.1547 | 30.1323 | 30.0509 | 29.9499 | 31.4499 |
| Other Liabilities, Total | 0.202 | 0.209 | 0.22008 | ||
| Total Preferred Shares Outstanding | 0 |
- Letni
- Četrtletno
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Čisti prihodki/začetna postavka | -13.1279 | -10.0924 | -11.8187 | -14.2431 | -5.00899 |
| Denarna sredstva iz poslovanja | -4.93688 | -6.17567 | -4.74143 | -4.2734 | -3.79671 |
| Denarna sredstva iz poslovanja | 0 | 0.03828 | 0.04756 | 0.01844 | 0.04322 |
| Amortization | 0 | 0.41875 | 0.3253 | 0.3253 | |
| Nedenarne postavke | 8.1125 | 4.33743 | 6.1325 | 9.55825 | 0.43553 |
| Spremembe v obratnem kapitalu | 0.07855 | -0.45901 | 0.47842 | 0.0677 | 0.40824 |
| Denarna sredstva pri naložbenju | -3.91768 | -0.30579 | -0.52546 | 1.4616 | -2.73519 |
| Kapitalski izdatki | 0 | -0.01579 | -0.17546 | -0.0384 | -0.03019 |
| Celotne druge postavke denarnih tokov pri naložbenju | -3.91768 | -0.29 | -0.35 | 1.5 | -2.705 |
| Denarna sredstva pri financiranju | 31.5658 | 9.4069 | 5.70262 | 2.52832 | 7.38295 |
| Postavke denarnega toka pri financiranju | 0.01403 | 0 | |||
| Izdaja (odplačilo) delnic, neto | 31.5658 | 9.4069 | 5.68858 | 2.52832 | 10.3829 |
| Neto sprememba denarnih sredstev | 22.7112 | 2.92544 | 0.43574 | -0.28348 | 0.85105 |
| Denarna sredstva Plačane obresti | 0.00182 | 0.03989 | 0 | 0.27243 | |
| Izdaja (odplačilo) dolga, neto | 0 | -3 |
| Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.467 | -3.879 | -13.1279 | -9.05688 | -4.66927 |
| Cash From Operating Activities | -3.503 | -1.197 | -4.93688 | -3.89271 | -2.41195 |
| Cash From Operating Activities | 0 | 0 | 0 | ||
| Non-Cash Items | 4.12 | 2.364 | 8.1125 | 5.26318 | 2.06069 |
| Cash Interest Paid | 2 | 1 | 0.00182 | 0.00168 | 0.0014 |
| Changes in Working Capital | -0.156 | 0.318 | 0.07855 | -0.09901 | 0.19663 |
| Cash From Investing Activities | 2.1 | 1.85 | -3.91768 | -6.72434 | -7.72385 |
| Capital Expenditures | 0 | 0 | 0 | ||
| Other Investing Cash Flow Items, Total | 2.1 | 1.85 | -3.91768 | -6.72434 | -7.72385 |
| Cash From Financing Activities | 0.007 | 0 | 31.5658 | 31.4222 | 31.4222 |
| Financing Cash Flow Items | 0 | -2.54893 | -2.54893 | ||
| Issuance (Retirement) of Stock, Net | 0.007 | 0 | 31.5658 | 33.9711 | 33.9711 |
| Net Change in Cash | -1.396 | 0.653 | 22.7112 | 20.8051 | 21.2864 |
| Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.2268 | 1307142 | 7144 | 2022-12-31 | LOW |
| Titterton (Lewis H Jr) | Individual Investor | 2.5031 | 774070 | 0 | 2023-01-17 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 2.0131 | 622544 | 853 | 2022-12-31 | LOW |
| Kumar (Amit) | Individual Investor | 1.4943 | 462100 | 0 | 2023-01-17 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.9353 | 289238 | -2985 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.887 | 274289 | 3626 | 2022-12-31 | LOW |
| Long Focus Capital Management LLC | Hedge Fund | 0.5358 | 165701 | 0 | 2022-12-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3302 | 102100 | 0 | 2022-12-31 | LOW |
| Baskies (Arnold M) | Individual Investor | 0.3234 | 100000 | 0 | 2023-01-17 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.2297 | 71023 | 31115 | 2022-12-31 | MED |
| Raymond James & Associates, Inc. | Research Firm | 0.185 | 57217 | -3629 | 2022-12-31 | LOW |
| Newton Investment Management North America, LLC | Investment Advisor | 0.179 | 55350 | 0 | 2022-12-31 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1777 | 54948 | 0 | 2022-12-31 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.1582 | 48925 | -714 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1549 | 47900 | -9300 | 2022-12-31 | HIGH |
| Citadel Advisors LLC | Hedge Fund | 0.1536 | 47506 | 27896 | 2022-12-31 | HIGH |
| Gottschalk (Emily) | Individual Investor | 0.1477 | 45665 | 0 | 2023-01-17 | LOW |
| BNY Mellon Asset Management | Investment Advisor | 0.1367 | 42268 | -238 | 2022-12-31 | LOW |
| Cambridge Investment Research Advisors, Inc. | Investment Advisor | 0.1297 | 40100 | 25100 | 2022-12-31 | LOW |
| Corecap Advisors Inc | Investment Advisor/Hedge Fund | 0.1171 | 36209 | -1177 | 2022-12-31 | MED |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group500K+
Borzni posredniki
92K+
Aktivne stranke mesečno
$53M+
Mesečni obseg naložb
$30M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
Trgovalna provizija
0
- 1:1
Vzvod
1:1
- 20
- 100
- 500
- 1000
- 10000
Naložbe
Velikost posla (finančni vzvod x naložba):
Odpiranje
Zapiranje
Kratka Dolga
Anixa Biosciences, Inc. Company profile
O družbi Anixa Biosciences, Inc.
Anixa Biosciences, Inc. je biotehnološko podjetje. Družba razvija terapije in cepiva, ki se osredotočajo na onkologijo in nalezljive bolezni. Družba razvija tehnologijo celic T s himeričnim endokrinim receptorjem, tehnologijo celic T s himeričnim antigenskim receptorjem (CAR-T), ki se osredotoča na zdravljenje raka na jajčnikih, in protivirusna zdravila za zdravljenje bolezni COVID-19, ki se osredotočajo na zaviranje nekaterih funkcij virusnih beljakovin virusa. Razvija tudi cepivo proti trojno negativnemu raku dojk (TNBC), smrtonosni obliki raka dojk, in cepivo proti raku jajčnikov. Njegova tehnologija CAR-T se lahko uporablja za zdravljenje več vrst solidnih tumorjev. Segmenti družbe vključujejo terapije CAR-T, cepiva proti raku, protivirusne terapije, dejavnosti diagnostike raka in dejavnosti licenciranja patentov. Njena hčerinska družba Certainty Therapeutics, Inc. (Certainty), razvija zdravila za imunoterapijo proti raku.
| Industry: | Biotechnology & Medical Research (NEC) |
3150 Almaden Expy Ste 250
SAN JOSE
CALIFORNIA 95118
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 500.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com